Business Description
Takeda Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3463000004
Share Class Description:
LTS:0RN3: Ordinary SharesCompare
Compare
Traded in other countries / regions
4502.JapanTAK.USATAK.MexicoTKDA.GermanyTKD.AustriaTAKP34.Brazil0RN3.UK IPO Date
2017-02-24Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.69 | |||||
| Debt-to-EBITDA | 4.31 | |||||
| Interest Coverage | 1.93 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.03 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | 19.7 | |||||
| 3-Year EPS without NRI Growth Rate | 35.6 | |||||
| 3-Year FCF Growth Rate | -8.8 | |||||
| 3-Year Book Growth Rate | 10.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 7.13 | |||||
| Future 3-5Y Total Revenue Growth Rate | 0.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | |||||
| Quick Ratio | 0.55 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 286.98 | |||||
| Days Sales Outstanding | 63.85 | |||||
| Days Payable | 109.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 1.66 | |||||
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 2.64 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.52 | |||||
| Operating Margin % | 8.08 | |||||
| Net Margin % | 4.28 | |||||
| FCF Margin % | -3.47 | |||||
| ROE % | 2.68 | |||||
| ROA % | 1.25 | |||||
| ROIC % | 3 | |||||
| ROC (Joel Greenblatt) % | 17.82 | |||||
| ROCE % | 2.71 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 36.32 | |||||
| Forward PE Ratio | 23.36 | |||||
| PE Ratio without NRI | 36.32 | |||||
| Shiller PE Ratio | 33.11 | |||||
| Price-to-Owner-Earnings | 16.98 | |||||
| PEG Ratio | 3.63 | |||||
| PS Ratio | 1.55 | |||||
| PB Ratio | 0.95 | |||||
| Price-to-Operating-Cash-Flow | 8.82 | |||||
| EV-to-EBIT | 33.21 | |||||
| EV-to-EBITDA | 9.89 | |||||
| EV-to-Revenue | 2.57 | |||||
| EV-to-FCF | -83.42 | |||||
| Price-to-Projected-FCF | 0.66 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.84 | |||||
| Earnings Yield (Greenblatt) % | 3.01 | |||||
| FCF Yield % | -2.02 | |||||
| Forward Rate of Return (Yacktman) % | 20.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Takeda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 27,281.359 | ||
| EPS (TTM) (€) | 0.74 | ||
| Beta | -0.02 | ||
| Volatility % | 2.1 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 37.59 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 37.59 - 37.59 | ||
| Shares Outstanding (Mil) | 1,568.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takeda Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takeda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Takeda Pharmaceutical Co Ltd Frequently Asked Questions
What is Takeda Pharmaceutical Co Ltd(LTS:0RN3)'s stock price today?
The current price of LTS:0RN3 is €37.59. The 52 week high of LTS:0RN3 is €37.59 and 52 week low is €37.59.
When is next earnings date of Takeda Pharmaceutical Co Ltd(LTS:0RN3)?
The next earnings date of Takeda Pharmaceutical Co Ltd(LTS:0RN3) is 2024-05-10 Est..
Does Takeda Pharmaceutical Co Ltd(LTS:0RN3) pay dividends? If so, how much?
Takeda Pharmaceutical Co Ltd(LTS:0RN3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers